Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report
Abstract Background The treatment of advanced or metastatic renal cell carcinoma (RCC) has drastically changed since the approval of immune checkpoint therapy. Nivolumab is a treatment option for patients with metastatic RCC, previously treated with targeted antiangiogenic therapy. The efficacy of n...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-04-01
|
| Series: | BMC Urology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12894-018-0339-2 |
| _version_ | 1811325171377635328 |
|---|---|
| author | Go Noguchi Sohgo Tsutsumi Masato Yasui Shinji Ohtake Susumu Umemoto Noboru Nakaigawa Masahiro Yao Takeshi Kishida |
| author_facet | Go Noguchi Sohgo Tsutsumi Masato Yasui Shinji Ohtake Susumu Umemoto Noboru Nakaigawa Masahiro Yao Takeshi Kishida |
| author_sort | Go Noguchi |
| collection | DOAJ |
| description | Abstract Background The treatment of advanced or metastatic renal cell carcinoma (RCC) has drastically changed since the approval of immune checkpoint therapy. Nivolumab is a treatment option for patients with metastatic RCC, previously treated with targeted antiangiogenic therapy. The efficacy of nivolumab for patients with RCC was established by the Checkmate 025 clinical trial. Chromophobe RCC (CRCC) represents around 5% of RCC cases, but non-clear cell RCC (non-ccRCC) subtypes were excluded from the Checkmate 025 clinical trial. We report a case in which the use of nivolumab as the seventh-line therapy elicited a significant response in the treatment of metastatic CRCC with sarcomatoid differentiation. Case presentation We report a case of a 41-year-old woman with metastatic CRCC with sarcomatoid differentiation. She was treated with sunitinib, pazopanib, everolimus, sorafenib, axtinib, and temsirolimus, but treatment was discontinued because of disease progression or strong adverse events. Seventh-line treatment with nivolumab was initiated and significant clinical improvement was noted after 4 cycles. The treatment was well-tolerated with no significant side effects and the patient continues with nivolumab treatment at present. Conclusions Nivolumab may be an attractive treatment option for non-ccRCC patients with sarcomatoid differentiation that exhibited aggressive characteristics and poor prognosis. Further investigation is warranted. |
| first_indexed | 2024-04-13T14:28:28Z |
| format | Article |
| id | doaj.art-544510df5d054eafa15229681c37fa99 |
| institution | Directory Open Access Journal |
| issn | 1471-2490 |
| language | English |
| last_indexed | 2024-04-13T14:28:28Z |
| publishDate | 2018-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Urology |
| spelling | doaj.art-544510df5d054eafa15229681c37fa992022-12-22T02:43:16ZengBMCBMC Urology1471-24902018-04-011811410.1186/s12894-018-0339-2Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case reportGo Noguchi0Sohgo Tsutsumi1Masato Yasui2Shinji Ohtake3Susumu Umemoto4Noboru Nakaigawa5Masahiro Yao6Takeshi Kishida7Department of Urology, Kanagawa Cancer CenterDepartment of Urology, Kanagawa Cancer CenterDepartment of Urology, Kanagawa Cancer CenterDepartment of Urology, Yokohama City University Graduate School of MedicineDepartment of Urology, Kanagawa Cancer CenterDepartment of Urology, Yokohama City University Graduate School of MedicineDepartment of Urology, Yokohama City University Graduate School of MedicineDepartment of Urology, Kanagawa Cancer CenterAbstract Background The treatment of advanced or metastatic renal cell carcinoma (RCC) has drastically changed since the approval of immune checkpoint therapy. Nivolumab is a treatment option for patients with metastatic RCC, previously treated with targeted antiangiogenic therapy. The efficacy of nivolumab for patients with RCC was established by the Checkmate 025 clinical trial. Chromophobe RCC (CRCC) represents around 5% of RCC cases, but non-clear cell RCC (non-ccRCC) subtypes were excluded from the Checkmate 025 clinical trial. We report a case in which the use of nivolumab as the seventh-line therapy elicited a significant response in the treatment of metastatic CRCC with sarcomatoid differentiation. Case presentation We report a case of a 41-year-old woman with metastatic CRCC with sarcomatoid differentiation. She was treated with sunitinib, pazopanib, everolimus, sorafenib, axtinib, and temsirolimus, but treatment was discontinued because of disease progression or strong adverse events. Seventh-line treatment with nivolumab was initiated and significant clinical improvement was noted after 4 cycles. The treatment was well-tolerated with no significant side effects and the patient continues with nivolumab treatment at present. Conclusions Nivolumab may be an attractive treatment option for non-ccRCC patients with sarcomatoid differentiation that exhibited aggressive characteristics and poor prognosis. Further investigation is warranted.http://link.springer.com/article/10.1186/s12894-018-0339-2Non-clear renal cell carcinomaSarcomatoid differentiationImmune-checkpoint inhibitorNivolumab |
| spellingShingle | Go Noguchi Sohgo Tsutsumi Masato Yasui Shinji Ohtake Susumu Umemoto Noboru Nakaigawa Masahiro Yao Takeshi Kishida Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report BMC Urology Non-clear renal cell carcinoma Sarcomatoid differentiation Immune-checkpoint inhibitor Nivolumab |
| title | Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report |
| title_full | Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report |
| title_fullStr | Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report |
| title_full_unstemmed | Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report |
| title_short | Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report |
| title_sort | significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation a case report |
| topic | Non-clear renal cell carcinoma Sarcomatoid differentiation Immune-checkpoint inhibitor Nivolumab |
| url | http://link.springer.com/article/10.1186/s12894-018-0339-2 |
| work_keys_str_mv | AT gonoguchi significantresponsetonivolumabformetastaticchromophoberenalcellcarcinomawithsarcomatoiddifferentiationacasereport AT sohgotsutsumi significantresponsetonivolumabformetastaticchromophoberenalcellcarcinomawithsarcomatoiddifferentiationacasereport AT masatoyasui significantresponsetonivolumabformetastaticchromophoberenalcellcarcinomawithsarcomatoiddifferentiationacasereport AT shinjiohtake significantresponsetonivolumabformetastaticchromophoberenalcellcarcinomawithsarcomatoiddifferentiationacasereport AT susumuumemoto significantresponsetonivolumabformetastaticchromophoberenalcellcarcinomawithsarcomatoiddifferentiationacasereport AT noborunakaigawa significantresponsetonivolumabformetastaticchromophoberenalcellcarcinomawithsarcomatoiddifferentiationacasereport AT masahiroyao significantresponsetonivolumabformetastaticchromophoberenalcellcarcinomawithsarcomatoiddifferentiationacasereport AT takeshikishida significantresponsetonivolumabformetastaticchromophoberenalcellcarcinomawithsarcomatoiddifferentiationacasereport |